Moreover, the succinylation-based prognostic model exhibited significant clinical relevance across multiple independent cohorts, which indicated that ATP6V1C2, CAPS, DAPK1, P4HA1, PCED1A, RASL10B, AGT, EREG, HYAL1, SARAF, and SLC4A4 hold potential as robust prognostic biomarkers in CRC. This evidence concerns the gene CAPS and colorectal carcinoma.